

Listing of the Claims:

1-37. (Cancelled)

38. (Previously Presented) A pharmaceutical composition comprising an isolated hyperimmune serum-reactive antigen fragment comprising an amino acid sequence encoded by a nucleic acid molecule fragment of SEQ ID NO:110 and comprising amino acids 4-37, 40-46, 52-57, 199-205, 222-229, 236-244, 250-267, 269-282, 27-197, 86-109, and/or 104-127 of SEQ ID NO:288.

39-46. (Cancelled)

47. (Withdrawn) The pharmaceutical composition of claim 38, further comprising at least two different hyperimmune serum-reactive antigens and/or fragments.

48. (Cancelled)

49. (Previously Presented) The pharmaceutical composition of claim 38, further comprising an immunostimulatory substance.

50. (Previously Presented) The pharmaceutical composition of claim 49, wherein the immunostimulatory substance is a polycationic polymer, an immunostimulatory deoxynucleotide (ODN), a peptide containing at least two LysLeuLys motifs, a neuroactive compound, alum, or a Freund's complete or incomplete adjuvant.

51. (Previously Presented) The pharmaceutical composition of claim 50, wherein the polycationic polymer is a polycationic peptide.

52. (Previously Presented) The pharmaceutical composition of claim 50, wherein the neuroactive compound is human growth hormone.

53. (Previously Presented) The pharmaceutical composition of claim 38, wherein the composition is a vaccine.

54. (Previously Presented) The pharmaceutical composition of claim 53, wherein the vaccine is a vaccine for treatment and/or prevention of *H. pylori* infection.

55. (Withdrawn) A method of vaccinating a subject comprising:
- obtaining a pharmaceutical composition of claim 45; and
- administering the pharmaceutical composition to a subject;
- wherein the subject is vaccinated.
56. (Withdrawn) The method of claim 55, wherein the subject is a human.
57. (Withdrawn) The method of claim 55, wherein the method is a method of treating and/or preventing *H. pylori* infection in the subject.
58. (Withdrawn) The method of claim 55, wherein the hyperimmune serum-reactive antigen or fragment is directed against *H. pylori*.
59. (Withdrawn) The method of claim 55, wherein the pharmaceutical composition comprises at least two different hyperimmune serum-reactive antigens or fragments thereof.
60. (Withdrawn) The method of claim 59, wherein the at least two different hyperimmune serum-reactive antigens or fragments thereof are both directed against *H. pylori*.